(NASDAQ: TECH) Bio Techne's forecast annual revenue growth rate of 8.18% is not forecast to beat the US Biotechnology industry's average forecast revenue growth rate of 36.14%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 9.23%.
Bio Techne's revenue in 2024 is $1,171,583,000.On average, 4 Wall Street analysts forecast TECH's revenue for 2025 to be $194,454,644,892, with the lowest TECH revenue forecast at $192,549,055,535, and the highest TECH revenue forecast at $195,603,750,390. On average, 4 Wall Street analysts forecast TECH's revenue for 2026 to be $212,827,780,402, with the lowest TECH revenue forecast at $210,309,186,480, and the highest TECH revenue forecast at $217,306,781,352.
In 2027, TECH is forecast to generate $237,481,432,090 in revenue, with the lowest revenue forecast at $230,069,288,512 and the highest revenue forecast at $244,893,575,668.